Pfizer Inc. (NYSE:PFE) Shares Sold by Kahn Brothers Group Inc.

Kahn Brothers Group Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 23.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 761,090 shares of the biopharmaceutical company's stock after selling 235,935 shares during the period. Pfizer accounts for approximately 4.3% of Kahn Brothers Group Inc.'s holdings, making the stock its 12th biggest position. Kahn Brothers Group Inc.'s holdings in Pfizer were worth $20,192,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC acquired a new position in Pfizer during the 4th quarter worth approximately $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.36 during midday trading on Tuesday, hitting $22.73. The company had a trading volume of 8,300,807 shares, compared to its average volume of 40,552,791. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a fifty day simple moving average of $23.96 and a 200 day simple moving average of $25.48. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $129.21 billion, a price-to-earnings ratio of 16.10, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.82 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.57%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

Several research analysts have weighed in on PFE shares. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.